



Newsletter HIT-CF Europe


March 2019




The goal of HIT-CF Europe is to evaluate the efficacy and safety of four drug candidates in patients with CF and rare mutations, pre-selected by their mini-intestines in the laboratory. The first part of the HIT-CF project aims at enrolling 500 people with CF with two rare CFTR-mutations from across Europe. A biopsy from these people will be taken and organoids will be generated. Watch the movie to find out how a rectal biopsy is obtained!



We take some tissue from the intestine



This tissue is cultured in the lab



The result is an organoid



On this organoid we test medicines




And we bring the correct medicines to the patients

First patients enrolled in HIT-CF!

25 people from 5 countries have been included so far: 13 people from the Netherlands, 8 from the Czech Republic, 2 from Israel, 1 from Austria and 1 person from Germany (both via the Netherlands). Also in Belgium, the team is now ready to start enrolling patients. This brings the total number of countries where people can participate in HIT-CF to 6 (green in map). We expect 23 extra hospitals in Portugal, Spain, France, United Kingdom, Italy, Sweden, Poland, Denmark and Switzerland (orange in map) to start including people in the following months!

HIT-CF welcomes Proteostasis Therapeutics and Eloxix Pharmaceuticals to the consortium!

Because their drug candidates aim to improve CFTR function in new ways, **people with specific CFTR mutations that previously could not participate in the study are now able to join**. Please check the updated criteria [here](#). To learn more about the pharmaceutical companies and their new compounds, read the press releases [here](#).




Our labs started drug candidate testing in the first organoids!

Over the past year, our lab technicians in Utrecht, Leuven and Lisbon have been working hard to obtain standardized organoid screening results. They have now successfully completed this test phase.

The organoids grown from the intestinal tissue from the first included patients have been shipped to our three labs. There, our lab technicians have started with testing the drug candidates in the organoids (screening).

Do you want to participate, or do you want more info about the HIT-CF project? Visit [the HIT-CF website](#) or send an e-mail to HITCF@umcutrecht.nl



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 755021

Contact information: HIT-CF Europe, Joseph Borlélaan 12, 1160 Brussels, Belgium